ASX | News Release Appointment of Company Secretary and change of Registered Office‌ Perth, Australia, 24th July 2017: Phylogica Ltd (ASX:PYC) (Phylogica or the Company), a drug discovery company developing the next generation of intracellular biologic therapeutics, is pleased to announce:

Appointment of Mr Kevin Hart as Company Secretary and CFO.

Mr Hart is a Chartered Accountant with over 30 years' experience in accounting and the management and administration of public listed entities.

He is currently a partner in an advisory firm Endeavour Corporate which specialises in the provision of company secretarial and accounting services to ASX listed entities.

Mr Graeme Boden has retired as Company Secretary. The Board would like to thank Graeme for his contribution to the Company and wishes him well in his future endeavours.

Change of Registered Office

In accordance with Listing Rule 3.14 we advise that the Phylogica Ltd Registered Office has relocated to:

Suite 8, 7 The Esplanade Mt Pleasant WA 6153 Ph: +61 8 9316 9100‌‌‌

Fax: +61 8 9315 5475

The Company's principal place of business, telephone number, and facsimile number remain unchanged.

-ENDS-

Tel: +61 8 9316 9100 | Fax: +61 8 9315 5475

www.phylogica.com

Phylogica Ltd

ABN 48 098 391 961

For further information, please contact:

Investors

Media

Stephanie Unwin

Chair

E: stephanieu@phylogica.com M: 0411 132 287

Ben Walsh

WE Buchan

E: bwalsh@buchanwe.com.au M: 0411 520 012

About Phylogica‌

Phylogica Limited (ASX: PYC) is an oncology-focussed biotech company discovering and developing a new generation of biologics-based therapies against intracellular cancer targets. The company was originally spun out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). Phylogica controls access to the world's most structurally diverse source of peptides - called Phylomers. The company specialises in Phylomer-based solutions to discover and deliver novel biologics drugs against intractable intracellular cancer targets with unprecedented potencies. Phylogica is advancing its proprietary oncology programmes developing first-in-class therapies against transcription factors such as Myc and Stat5. These targets play a critical role in many common cancers such as breast, lung, prostate and pancreatic, but have proven undruggable with conventional small molecule therapies. Within the last six years, the company has entered into discovery collaborations with Roche, Genentech, MedImmune, Pfizer, Janssen and Cubist Pharmaceuticals.

2

Phylogica Limited published this content on 24 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 July 2017 03:29:01 UTC.

Original documenthttp://phylogica.com/wp-content/uploads/2017/07/1693759.pdf

Public permalinkhttp://www.publicnow.com/view/79C4FC5B31FDE2B6C410649EB8DEF572B545C732